Jason Gerberry
Stock Analyst at B of A Securities
(3.74)
# 681
Out of 4,884 analysts
156
Total ratings
55.86%
Success rate
5.39%
Average return
Main Sectors:
Stocks Rated by Jason Gerberry
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PROK ProKidney | Downgrades: Underperform | $3 → $1 | $0.64 | +56.94% | 4 | Jun 30, 2025 | |
| LQDA Liquidia | Maintains: Buy | $25 → $23 | $12.19 | +88.68% | 2 | Jun 11, 2025 | |
| EXEL Exelixis | Maintains: Neutral | $45 → $46 | $46.15 | -0.33% | 3 | Jun 5, 2025 | |
| TEVA Teva Pharmaceutical Industries | Maintains: Buy | $20 → $22 | $17.01 | +29.34% | 14 | May 8, 2025 | |
| PCVX Vaxcyte | Maintains: Buy | $157 → $137 | $33.25 | +312.03% | 9 | Apr 1, 2025 | |
| IMVT Immunovant | Maintains: Buy | $38 → $33 | $16.95 | +94.69% | 5 | Mar 20, 2025 | |
| VTRS Viatris | Maintains: Underperform | $11 → $10 | $9.32 | +7.30% | 3 | Feb 28, 2025 | |
| AXSM Axsome Therapeutics | Maintains: Buy | $143 → $167 | $105.44 | +58.38% | 5 | Feb 11, 2025 | |
| CPRX Catalyst Pharmaceuticals | Reiterates: Buy | $30 | $21.46 | +39.79% | 2 | Jan 9, 2025 | |
| ACLX Arcellx | Maintains: Buy | $84 → $100 | $67.16 | +48.90% | 4 | Nov 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $52 → $62 | $14.63 | +323.79% | 1 | Sep 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $20 → $24 | $3.63 | +561.16% | 1 | Sep 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $67 → $68 | $43.00 | +58.14% | 5 | Jul 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $21 → $20 | $19.00 | +5.26% | 3 | Jun 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $41 → $31 | $28.83 | +7.53% | 6 | Apr 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $600 → $550 | $9.00 | +6,011.11% | 3 | Mar 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $27 → $29 | $28.85 | +0.52% | 9 | Jan 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $29 → $37 | $16.79 | +120.37% | 2 | Jan 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $52 → $56 | $33.26 | +68.37% | 2 | Jan 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $30 | $32.16 | -6.72% | 2 | Jan 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $63 | $23.20 | +171.55% | 1 | Nov 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $204 → $217 | $109.45 | +98.26% | 5 | Aug 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $100 → $50 | $5.61 | +791.27% | 6 | Aug 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $450 → $500 | $780.67 | -35.95% | 15 | May 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $9 | $1.19 | +656.30% | 1 | Dec 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $37 → $25 | $9.96 | +151.00% | 3 | Oct 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $45 → $5 | $2.23 | +124.22% | 2 | Dec 2, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $27 | $7.06 | +282.44% | 4 | Mar 24, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $20 | $0.81 | +2,369.14% | 1 | Jul 16, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $17 → $10 | $0.71 | +1,315.03% | 1 | Jul 15, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Neutral | $95 | $189.28 | -49.81% | 10 | May 18, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Buy | $60 | $46.92 | +27.88% | 7 | Oct 17, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Neutral | $37 | $25.38 | +45.78% | 4 | Oct 17, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Neutral | $90 | $80.93 | +11.21% | 11 | Oct 17, 2019 |
ProKidney
Jun 30, 2025
Downgrades: Underperform
Price Target: $3 → $1
Current: $0.64
Upside: +56.94%
Liquidia
Jun 11, 2025
Maintains: Buy
Price Target: $25 → $23
Current: $12.19
Upside: +88.68%
Exelixis
Jun 5, 2025
Maintains: Neutral
Price Target: $45 → $46
Current: $46.15
Upside: -0.33%
Teva Pharmaceutical Industries
May 8, 2025
Maintains: Buy
Price Target: $20 → $22
Current: $17.01
Upside: +29.34%
Vaxcyte
Apr 1, 2025
Maintains: Buy
Price Target: $157 → $137
Current: $33.25
Upside: +312.03%
Immunovant
Mar 20, 2025
Maintains: Buy
Price Target: $38 → $33
Current: $16.95
Upside: +94.69%
Viatris
Feb 28, 2025
Maintains: Underperform
Price Target: $11 → $10
Current: $9.32
Upside: +7.30%
Axsome Therapeutics
Feb 11, 2025
Maintains: Buy
Price Target: $143 → $167
Current: $105.44
Upside: +58.38%
Catalyst Pharmaceuticals
Jan 9, 2025
Reiterates: Buy
Price Target: $30
Current: $21.46
Upside: +39.79%
Arcellx
Nov 6, 2024
Maintains: Buy
Price Target: $84 → $100
Current: $67.16
Upside: +48.90%
Sep 24, 2024
Maintains: Buy
Price Target: $52 → $62
Current: $14.63
Upside: +323.79%
Sep 10, 2024
Maintains: Buy
Price Target: $20 → $24
Current: $3.63
Upside: +561.16%
Jul 23, 2024
Maintains: Buy
Price Target: $67 → $68
Current: $43.00
Upside: +58.14%
Jun 11, 2024
Maintains: Buy
Price Target: $21 → $20
Current: $19.00
Upside: +5.26%
Apr 1, 2024
Downgrades: Underperform
Price Target: $41 → $31
Current: $28.83
Upside: +7.53%
Mar 25, 2024
Maintains: Buy
Price Target: $600 → $550
Current: $9.00
Upside: +6,011.11%
Jan 2, 2024
Maintains: Neutral
Price Target: $27 → $29
Current: $28.85
Upside: +0.52%
Jan 2, 2024
Maintains: Buy
Price Target: $29 → $37
Current: $16.79
Upside: +120.37%
Jan 2, 2024
Maintains: Buy
Price Target: $52 → $56
Current: $33.26
Upside: +68.37%
Jan 2, 2024
Downgrades: Underperform
Price Target: $30
Current: $32.16
Upside: -6.72%
Nov 17, 2023
Initiates: Neutral
Price Target: $63
Current: $23.20
Upside: +171.55%
Aug 10, 2023
Maintains: Buy
Price Target: $204 → $217
Current: $109.45
Upside: +98.26%
Aug 8, 2023
Downgrades: Underperform
Price Target: $100 → $50
Current: $5.61
Upside: +791.27%
May 24, 2023
Maintains: Buy
Price Target: $450 → $500
Current: $780.67
Upside: -35.95%
Dec 12, 2022
Downgrades: Underperform
Price Target: $9
Current: $1.19
Upside: +656.30%
Oct 14, 2022
Downgrades: Underperform
Price Target: $37 → $25
Current: $9.96
Upside: +151.00%
Dec 2, 2021
Downgrades: Underperform
Price Target: $45 → $5
Current: $2.23
Upside: +124.22%
Mar 24, 2021
Downgrades: Underperform
Price Target: $27
Current: $7.06
Upside: +282.44%
Jul 16, 2020
Initiates: Neutral
Price Target: $20
Current: $0.81
Upside: +2,369.14%
Jul 15, 2020
Downgrades: Neutral
Price Target: $17 → $10
Current: $0.71
Upside: +1,315.03%
May 18, 2020
Reinstates: Neutral
Price Target: $95
Current: $189.28
Upside: -49.81%
Oct 17, 2019
Reinstates: Buy
Price Target: $60
Current: $46.92
Upside: +27.88%
Oct 17, 2019
Reinstates: Neutral
Price Target: $37
Current: $25.38
Upside: +45.78%
Oct 17, 2019
Reinstates: Neutral
Price Target: $90
Current: $80.93
Upside: +11.21%